Ardelyx announced on March 31, 2025, that an abstract detailing a post-hoc analysis of the OPTIMIZE Study for XPHOZAH was accepted for a poster presentation. The presentation will take place at the National Kidney Foundation (NKF) Spring Clinical Meetings, scheduled for April 10-13, 2025, in Boston.
The OPTIMIZE Study was an open-label clinical trial involving 330 patients with chronic kidney disease on dialysis and hyperphosphatemia. It was designed to evaluate different methods of initiating XPHOZAH to optimize phosphorus management in both binder-naïve and binder-treated patients.
The post-hoc analysis, titled 'Tenapanor-Treated Patients Using Over-the-Counter Antidiarrheal Agents Saw Decreased Stool Frequency and Improved Stool Consistency,' will provide insights into managing diarrhea, a common side effect of XPHOZAH, potentially improving patient adherence and treatment outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.